quantisnow
FeedTopReportsPricing
⌘K
Live feed
06:58:50·25d
SECFiling
Neumora Therapeutics Inc. logo

Neumora Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

NMRA· Neumora Therapeutics Inc.
Health Care
Original source

Companies

  • NMRA
    Neumora Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Feb 17UpdateWilliam Blair-
  • Jan 12UpdateLeerink Partners$8.00
  • Dec 1UpdateRBC Capital Mkts$7.00
  • Oct 27UpdateGuggenheim$14.00
  • Sep 16UpdateAnalyst-
  • Apr 2UpdateBofA Securities$1.00

Related

  • SEC6d
    SEC Form DEFA14A filed by Neumora Therapeutics Inc.
  • SEC6d
    SEC Form DEF 14A filed by Neumora Therapeutics Inc.
  • PR18d
    Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
  • SEC25d
    SEC Form S-8 filed by Neumora Therapeutics Inc.
  • SEC25d
    SEC Form 10-K filed by Neumora Therapeutics Inc.
  • PR25d
    Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
  • PR39d
    Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
  • INSIDER63d
    Officer Aurora Daljit Singh sold $21,917 worth of shares (6,165 units at $3.56), decreasing direct ownership by 7% to 82,770 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022